1-6 of 6
Xiaofei Zhou, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962)

Owen A. O'Connor, MD PhD, Muhit Özcan, MD, Eric D. Jacobsen, MD, Josep Maria Roncero Vidal, MD, Judith Trotman, MBChB, Judit Demeter, MD PhD DsC, Tamás Masszi, MD, Juliana Pereira, MD PhD, Radhakrishnan Ramchandren, MD, Francesco A. d'Amore, MD PhD, Francine Foss, MD, Won-Seog Kim, MD PhD, John P. Leonard, MD, Carlos Sérgio Chiattone, MD PhD, Pier Luigi Zinzani, MD PhD, Hua Liu, PhD, JungAh Jung, PhD, Xiaofei Zhou, PhD, E. Jane Leonard, MSc, Claudio Dansky Ullmann, MD, Andrei R. Shustov, MD
Journal: Blood
Blood (2015) 126 (23): 341.
https://doi.org/10.1182/blood.V126.23.341.341
Published: 2015
Journal Articles

Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas

Kevin R. Kelly, MD, PhD, Daniel O. Persky, MD, Daruka Mahadevan, MD, PhD, Thomas P. Miller, MD, Soham D. Puvvada, MD, Kevin McDonagh, MD, John Hayslip, MD, Steven I. Park, MD, Jia Ruan, MD, PhD, Peter J. Rosen, MD, Swaminathan Padmanabhan Iyer, MD, MB, BS, Alexandra Stefanovic, MD, Bin Zhang, ScD, Xiaofei Zhou, PhD, Claudio Dansky Ullmann, MD, E. Jane Leonard, MSc, Jonathan W. Friedberg, MD
Journal: Blood
Blood (2013) 122 (21): 3027.
https://doi.org/10.1182/blood.V122.21.3027.3027
Published: 2013
Journal Articles

Integrated Safety Analysis of Single-Agent MLN8237 (alisertib), an Investigational Aurora A Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies and Solid Tumors

Ely Benaim, MD, Xiaofei Zhou, PhD, Hua Liu, PhD, E. Jane Leonard, MSc, Eric Freedland, Liviu Niculescu
Journal: Blood
Blood (2012) 120 (21): 3683.
https://doi.org/10.1182/blood.V120.21.3683.3683
Published: 2012
Journal Articles

Results From a Phase 1 Multicenter Trial of Alisertib (MLN8237)–An Investigational Aurora A Kinase Inhibitor–in Patients with Advanced Hematologic Malignancies

Kevin R. Kelly, MD, Swaminathan Padmanabhan, MBBS, MD, André Goy, MD, Jesus G. Berdeja, MD, Craig B. Reeder, MD, Kevin T. McDonagh, MD, Xiaofei Zhou, PhD, Hadi Danaee, SD, Hugh Xiao, PhD, Ely Benaim, MD, Thomas C. Shea, MD
Journal: Blood
Blood (2011) 118 (21): 2477.
https://doi.org/10.1182/blood.V118.21.2477.2477
Published: 2011
Journal Articles

Phase 2 Trial of Alisertib (MLN8237), An Investigational, Potent Inhibitor of Aurora A Kinase (AAK), in Patients (pts) with Aggressive B- and T-Cell Non-Hodgkin Lymphoma (NHL)

Jonathan Friedberg, MD, Daruka Mahadevan, MD, PhD, JungAh Jung, PhD, Daniel O. Persky, MD, Izidore S Lossos, MD, Hadi Danaee, SD, Xiaofei Zhou, PhD, E Jane Leonard, Steven H. Bernstein
Journal: Blood
Blood (2011) 118 (21): 95.
https://doi.org/10.1182/blood.V118.21.95.95
Published: 2011
Journal Articles

Phase I Study of An Investigational Aurora A Kinase Inhibitor MLN8237 In Patients with Advanced Hematologic Malignancies.

Swaminathan Padmanabhan, MBBS, MD, Thomas C. Shea, MD, Julie M. Vose, MD, Craig B. Reeder, MD, Jesus G Berdeja, MD, Kevin T. McDonagh, MD, Andre Goy, MD, Kevin R Kelly, MD, Xiaofei Zhou, PhD, Hua Liu, PhD, Howard Fingert, MD, Nathan Fowler, MD
Journal: Blood
Blood (2010) 116 (21): 2799.
https://doi.org/10.1182/blood.V116.21.2799.2799
Published: 2010